Placeholder Banner

Importation Scheme Will Jeopardize Patient Health, Do Little to Lower Drug Costs

“Patients deserve access to the medicines they need with out-of-pocket costs they can afford. Under no circumstance should we risk patient safety to achieve this goal, yet that’s exactly what this dangerous importation scheme will do."

December 18, 2019
Media Contact
Author-Profile-Andrew-Segerman

Washington, DC (December 18, 2019) – Following the release of the Trump administration’s drug importation proposal, BIO’s President and CEO Jim Greenwood issued the following statement:

“Patients deserve access to the medicines they need with out-of-pocket costs they can afford. Under no circumstance should we risk patient safety to achieve this goal, yet that’s exactly what this dangerous importation scheme will do. The idea that this plan will result in savings for patients at the pharmacy counter is a talking point that’s been debunked by nonpartisan budget experts and past FDA commissioners who served under both Republican and Democratic administrations.

“Following the recent vote on Speaker Pelosi’s extreme drug pricing plan, today’s announcement is the latest empty gesture from our elected lawmakers who want us to believe they’re serious about lowering patients’ prescription drug costs. It’s time Congress and the administration delivered a holistic solution that protects the health and well-being of patients and ensures medicines are affordable.”

Learn more:

 

###

Discover More
Ahead of tonight’s State of the Union Address, Jim Greenwood, President and CEO of the Biotechnology Innovation Organization, shared what he hopes President Trump will say to America’s patients counting on the development of new medicines and cures,…
In a new video, Alex Karnal, a life science investor and partner at Deerfield Management, shares why investing in new cures and treatments is personal, and he explains how President Trump’s plan to import foreign price controls would have an …
Rachel King is co-founder and CEO of GlycoMimetics, a biotech company based in Rockville, Maryland that is working hard to develop new treatments for patients with various diseases of the blood. In a new video, Mrs. King explains why President Trump…